U.S. market Closed. Opens in 21 hours 54 minutes

GMAB | Genmab A/S Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 19.73 - 19.96
52 Week Range 18.64 - 30.50
Beta 0.74
Implied Volatility 74.56%
IV Rank 33.14%
Day's Volume 899,322
Average Volume 1,490,533
Shares Outstanding 636,593,024
Market Cap 12,668,201,178
Sector Healthcare
Industry Biotechnology
IPO Date 2009-06-01
Valuation
Profitability
Growth
Health
P/E Ratio 11.37
Forward P/E Ratio 28.69
EPS 1.75
1YR Price Target 40.50
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 2,635
Country Denmark
Website GMAB
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
GMAB's peers: ASND, APLS, BGNE, AKRO, BPMC, DAWN, MRTX, AMLX, TERN, LEGN, PCVX, TVTX, ALEC, CYTK, EWTX
*Chart delayed
Analyzing fundamentals for GMAB we got that it has strong fundamentals where Valuation is considered to be undervalued, Profitability is very wealthy, Growth is exceptionally good and Health is strong. For more detailed analysis please see GMAB Fundamentals page.

Watching at GMAB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GMAB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙